Axovant Sciences Ltd (AXON) Short Interest Update

Axovant Sciences Ltd (NASDAQ:AXON) was the target of a significant growth in short interest during the month of December. As of December 31st, there was short interest totalling 4,519,607 shares, a growth of 51.1% from the December 14th total of 2,991,736 shares. Approximately 8.7% of the shares of the company are short sold. Based on an average daily trading volume, of 1,484,014 shares, the short-interest ratio is presently 3.0 days.

In related news, major shareholder Svf Investments (Uk) Ltd acquired 10,000,000 shares of the firm’s stock in a transaction that occurred on Tuesday, December 18th. The stock was acquired at an average price of $1.00 per share, for a total transaction of $10,000,000.00. Following the completion of the acquisition, the insider now owns 99,285,714 shares of the company’s stock, valued at approximately $99,285,714. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 6.00% of the company’s stock.

Several institutional investors and hedge funds have recently bought and sold shares of the company. Renaissance Technologies LLC increased its stake in shares of Axovant Sciences by 60.5% in the third quarter. Renaissance Technologies LLC now owns 2,091,700 shares of the biotechnology company’s stock worth $5,062,000 after purchasing an additional 788,100 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. increased its stake in shares of Axovant Sciences by 12.9% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 559,602 shares of the biotechnology company’s stock worth $1,354,000 after purchasing an additional 64,152 shares in the last quarter. BlackRock Inc. increased its stake in shares of Axovant Sciences by 13.5% in the third quarter. BlackRock Inc. now owns 1,424,710 shares of the biotechnology company’s stock worth $3,447,000 after purchasing an additional 169,918 shares in the last quarter. Tower Research Capital LLC TRC increased its stake in shares of Axovant Sciences by 1,627.0% in the second quarter. Tower Research Capital LLC TRC now owns 62,139 shares of the biotechnology company’s stock worth $141,000 after purchasing an additional 58,541 shares in the last quarter. Finally, Paloma Partners Management Co purchased a new position in shares of Axovant Sciences in the second quarter worth about $356,000. Hedge funds and other institutional investors own 7.71% of the company’s stock.

AXON opened at $1.08 on Wednesday. The stock has a market capitalization of $135.73 million, a PE ratio of -0.52 and a beta of 1.22. The company has a debt-to-equity ratio of 1.68, a current ratio of 1.97 and a quick ratio of 1.97. Axovant Sciences has a twelve month low of $0.93 and a twelve month high of $6.59.

Axovant Sciences (NASDAQ:AXON) last posted its earnings results on Wednesday, November 7th. The biotechnology company reported ($0.28) earnings per share for the quarter, topping the consensus estimate of ($0.38) by $0.10. On average, equities research analysts anticipate that Axovant Sciences will post -1.25 EPS for the current fiscal year.

A number of analysts recently issued reports on AXON shares. Zacks Investment Research upgraded shares of Axovant Sciences from a “hold” rating to a “buy” rating and set a $2.25 price objective for the company in a report on Tuesday, October 9th. BidaskClub upgraded shares of Axovant Sciences from a “strong sell” rating to a “sell” rating in a report on Tuesday, October 16th. ValuEngine upgraded shares of Axovant Sciences from a “hold” rating to a “buy” rating in a report on Thursday, November 1st. Cowen reiterated a “hold” rating on shares of Axovant Sciences in a research note on Thursday, September 20th. Finally, Oppenheimer reiterated a “hold” rating on shares of Axovant Sciences in a research note on Sunday, November 11th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and three have given a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of $3.81.

TRADEMARK VIOLATION NOTICE: “Axovant Sciences Ltd (AXON) Short Interest Update” was originally reported by Chaffey Breeze and is the property of of Chaffey Breeze. If you are viewing this report on another website, it was copied illegally and republished in violation of international trademark and copyright laws. The legal version of this report can be read at https://www.chaffeybreeze.com/2019/01/16/axovant-sciences-ltd-axon-short-interest-update.html.

About Axovant Sciences

Axovant Sciences Ltd., a clinical-stage biopharmaceutical company, engages in acquisition, development, and commercialization of therapeutics in the fields of neurology and psychiatry in the United States and the European Union. It focuses on developing AXO-Lenti-PD, an in vivo lentiviral gene therapy investigational product candidate for the one-time treatment of Parkinson's disease.

Featured Story: Front-End Load

Receive News & Ratings for Axovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply